ADMINISTRATION

Dosage recommendation Dementia

For the treatment of dementia one therapy course corresponds to a therapy duration of 4 weeks (5 applications/week). The effectiveness of therapy can be increased by repeated courses after treatment-free periods of 2 - 3 months until no further benefit is observed. In the following therapy courses the frequency of application can be reduced from daily applications to 2-3 applications per week.

Disorder

Daily dosage

Initiation of treatment

Duration of treatment

Vascular dementia

10 - 30 ml

as soon as possible

1 clyle: 5 days weekly/4weeks
2-4- cycles per year

Alzheimer's disease

10 - 30 ml

as soon as possible

1 cycle: 5 days weekly/4 weeks
2-4 cycles per year

ROUTE OF ADMINISTRATION

IV infusion

10ml - 50ml

diluted to at least 100ml total
volume with Saline, Ringer solution
or 5% glucose solution

Infuse within 15 minutes

To guarantee sterility, always use disposable one-way infusion sets and cannulas! 
Do not store the infusion solution, start the infusion as quickly as possibe after dilution!
Cerebrolysin® should not be mixed with balanced amino acid solutions, vitamins and cardiovascular medicinal products.

 

IV injection

up to 10ml

undiluted

inject slowly
over 3 minutes

IM injection

up to 5ml

undiluted

inject slowly
over 3 minutes

The IV or IM injection has to be administered immediately after opening the ampoule! 

STERILITY ASPECTS

Special precautions to guarantee sterility must be taken during dilution and administration of Cerebrolysin®:

  • Remove solution from ampoules immediately before use
  • Do not leave an open ampoule on the treatment table
  • Always use only disposable one-way IV infusions sets and cannulas
  • When Cerebrolysin® is administered via a long-term IV catheter, the catheter has to be rinsed before and after the application with physiological sodium chloride solution
  • Pay special attention to recommended infusion/injection times page before

More information please find in our Dosage Recommendation.

 

This information is based on the Austrian Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local EVER representative.